<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11076650</article-id><article-id pub-id-type="pmc">2363421</article-id><article-id pub-id-type="pii">6691485</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1485</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Induction chemotherapy followed by alternating chemo-radiotherapy in stage IV undifferentiated nasopharyngeal carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Benasso</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sanguineti</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>D'Amico</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Corv&#x000f2;</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Ricci</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Numico</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Guarneri</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vitale</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Pallestrini</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Santelli</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Rosso</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medical Oncology I, <label>2</label>Radiation Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova</aff><aff id="aff3"><label>3</label>Department of Medical Oncology, Ospedale S. Croce e Carle, Cuneo</aff><aff id="aff4"><label>4</label>Department of Medical Oncology, Ospedale Sanremo</aff><aff id="aff5"><label>5</label>Department of Otolaryngology, Ospedale S. Martino, Genova</aff><pub-date pub-type="epub"><day>22</day><month>11</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2000</year></pub-date><volume>83</volume><issue>11</issue><fpage>1437</fpage><lpage>1442</lpage><history><date date-type="received"><day>25</day><month>02</month><year>2000</year></date><date date-type="rev-recd"><day>25</day><month>07</month><year>2000</year></date><date date-type="accepted"><day>09</day><month>08</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>In locally advanced undifferentiated nasopharyngeal carcinoma (UNPC), concomitant chemo-radiotherapy is the only strategy that gave better results over radiation alone in a phase III trial. Adding effective chemotherapy to a concomitant chemo-radiotherapy programme may be a way to improve the results further. 30 patients with previously untreated T4 and/or N2&#x02013;3 undifferentiated nasopharyngeal carcinoma were consecutively enrolled and initially treated with 3 courses of epidoxorubicin, 90 mg/m2, day 1 and cisplatin, 40 mg/m2, days 1 and 2, every 3 weeks. After a radiological and clinical response assessment patients underwent 3 courses of cisplatin, 20 mg/m2/day, days 1&#x02013;4 and fluorouracil, 200 mg/m2/day, days 1&#x02013;4, i.v. bolus, (weeks 1, 4, 7) alternated to 3 courses of radiation (week 2&#x02013;3, 5&#x02013;6, 8&#x02013;9&#x02013;10), with a single daily fractionation, up to 70 Gy. WHO histology was type 2 in 30&#x00025; and type 3 in 70&#x00025; of the patients. 57&#x00025; had T4 and 77&#x00025; N2&#x02013;3 disease. All the patients are evaluable for toxicity and response. All but one received 3 courses of induction chemotherapy. Toxicity was mild to moderate in any case. At the end of the induction phase 10&#x00025; of CRs, 83.3&#x00025; of PRs and 6.7&#x00025; of SD were recorded. All the patients but one had the planned number of chemotherapy courses in the alternating phase and all received the planned radiation dose. One patient out of 3 developed grade III&#x02013;IV mucositis. Haematological toxicity was generally mild to moderate. At the final response evaluation 86.7&#x00025; of CRs and 13.3&#x00025; of PRs were observed. At a median follow-up of 31 months, 13.3&#x00025; of patients had a loco-regional progression and 20&#x00025; developed distant metastases. The 3-year actuarial progression-free survival and overall survival rates were 64&#x00025; and 83&#x00025;. Induction chemotherapy followed by alternating chemo-radiotherapy is feasible and patients' compliance optimal. This approach showed a very promising activity on locally advanced UNPC and merits to be investigated in phase III studies. &#x000a9; 2000 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>nasopharyngeal carcinoma</kwd><kwd>chemo-radiotherapy</kwd><kwd>combined treatments</kwd></kwd-group></article-meta></front></article>


